Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study, with the trial evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab versus pembrolizumab monotherapy in first-line patients with treatment-naïve, PD-L1-positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It reported that the interim analyses showed that INBRX-106 + pembrolizumab attained a 44.0% confirmed Objective Response Rate. In addition, the responding patients in the combination arm exhibited deeper overall tumor reductions, with the majority attaining target lesion shrinkage that exceeded 50%. Three patients also notably achieved a complete radiographic response.

In a separate development, Inhibrx Biosciences, Inc. (NASDAQ:INBX) received a rating update from Stifel on April 22. The firm lifted the price target on the stock to $300 from $150 and maintained a Buy rating on the shares.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates that were developed through proprietary modular protein engineering platforms. The company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106.

While we acknowledge the risk and potential of INBX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INBX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.